vs
ALUMIS INC.（ALMS）与Token Cat Ltd（TC）财务数据对比。点击上方公司名可切换其他公司
Token Cat Ltd的季度营收约是ALUMIS INC.的1.0倍（$2.8M vs $2.7M），ALUMIS INC.净利率更高（2225.1% vs -3.4%，领先2228.5%）
ALUMIS INC.是一家临床阶段生物制药企业，专注于研发针对自身免疫性疾病与炎症性疾病的创新靶向疗法，旗下多款核心候选产品处于临床试验阶段，致力于满足全球患者尚未被满足的医疗需求。
ALMS vs TC — 直观对比
营收规模更大
TC
是对方的1.0倍
$2.7M
净利率更高
ALMS
高出2228.5%
-3.4%
损益表 — Q2 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.7M | $2.8M |
| 净利润 | $59.3M | $-93.0K |
| 毛利率 | — | 79.0% |
| 营业利润率 | -5271.5% | -206.9% |
| 净利率 | 2225.1% | -3.4% |
| 营收同比 | — | -37.9% |
| 净利润同比 | 205.0% | 98.3% |
| 每股收益（稀释后） | $0.77 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALMSTC
| Q2 25 | $2.7M | $2.8M | ||
| Q1 25 | $17.4M | — | ||
| Q2 24 | — | $4.4M | ||
| Q2 23 | — | $12.7M | ||
| Q2 22 | — | $13.3M |
净利润ALMSTC
| Q2 25 | $59.3M | $-93.0K | ||
| Q1 25 | $-99.0M | — | ||
| Q2 24 | — | $-5.6M | ||
| Q2 23 | — | $-4.2M | ||
| Q2 22 | — | $-8.4M |
毛利率ALMSTC
| Q2 25 | — | 79.0% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | 69.2% | ||
| Q2 23 | — | 63.4% | ||
| Q2 22 | — | 81.0% |
营业利润率ALMSTC
| Q2 25 | -5271.5% | -206.9% | ||
| Q1 25 | -583.9% | — | ||
| Q2 24 | — | -146.9% | ||
| Q2 23 | — | -59.9% | ||
| Q2 22 | — | -49.6% |
净利率ALMSTC
| Q2 25 | 2225.1% | -3.4% | ||
| Q1 25 | -569.1% | — | ||
| Q2 24 | — | -125.9% | ||
| Q2 23 | — | -33.3% | ||
| Q2 22 | — | -62.9% |
每股收益（稀释后）ALMSTC
| Q2 25 | $0.77 | — | ||
| Q1 25 | $-1.82 | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $486.3M | $150.0K |
| 总债务越低越好 | — | $1.4M |
| 股东权益账面价值 | $485.3M | $4.6M |
| 总资产 | $610.9M | $28.4M |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资ALMSTC
| Q2 25 | $486.3M | $150.0K | ||
| Q1 25 | $208.7M | — | ||
| Q2 24 | — | $689.0K | ||
| Q2 23 | — | $3.0M | ||
| Q2 22 | — | $4.8M |
总债务ALMSTC
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | — | ||
| Q2 24 | — | $1.8M | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
股东权益ALMSTC
| Q2 25 | $485.3M | $4.6M | ||
| Q1 25 | $168.3M | — | ||
| Q2 24 | — | $-787.0K | ||
| Q2 23 | — | $9.1M | ||
| Q2 22 | — | $21.4M |
总资产ALMSTC
| Q2 25 | $610.9M | $28.4M | ||
| Q1 25 | $261.3M | — | ||
| Q2 24 | — | $12.5M | ||
| Q2 23 | — | $25.1M | ||
| Q2 22 | — | $40.6M |
负债/权益比ALMSTC
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-106.4M | $-23.7M |
| 自由现金流经营现金流 - 资本支出 | $-107.0M | — |
| 自由现金流率自由现金流/营收 | -4012.3% | — |
| 资本支出强度资本支出/营收 | 23.1% | — |
| 现金转化率经营现金流/净利润 | -1.79× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ALMSTC
| Q2 25 | $-106.4M | $-23.7M | ||
| Q1 25 | $-80.4M | — | ||
| Q2 24 | — | $-1.5M | ||
| Q2 23 | — | $-7.2M | ||
| Q2 22 | — | $-8.3M |
自由现金流ALMSTC
| Q2 25 | $-107.0M | — | ||
| Q1 25 | $-80.4M | — | ||
| Q2 24 | — | $-1.5M | ||
| Q2 23 | — | — | ||
| Q2 22 | — | $-8.3M |
自由现金流率ALMSTC
| Q2 25 | -4012.3% | — | ||
| Q1 25 | -462.3% | — | ||
| Q2 24 | — | -34.4% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | -62.2% |
资本支出强度ALMSTC
| Q2 25 | 23.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q2 24 | — | 0.0% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | 0.1% |
现金转化率ALMSTC
| Q2 25 | -1.79× | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
